This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most patients, with encouraging activity. Longer follow-up will be needed to confirm these data.
Learn more about applying for Radiation Oncologist – Head & Neck at Mayo Clinic
Ashish Jha and others showed how broken the current system is
By Sebastian Giebel. Treatment algorithms differ for adult patients with Philadelphia-negative (Ph-) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).
Violence and threats against health facilities and workers, both in peacetime and during armed conflict, and the criminalisation of medical care, such as abortion care,…
ISTH Academy; Presenters F. Oct 15 2024; 4147521;
Chaired by Dr. Heather McArthur, University of Texas Southwestern Medical Center, and Dr. Sumanta Pal, City of Hope Comprehensive Cancer Center, this international virtual conference…
Globally, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death [1]. Over 2.2 million new cases were diagnosed…
Glofit-GemOx had a significant overall survival benefit compared with R-GemOx, supporting its use in transplant-ineligible patients with relapsed or refractory diffuse large B-cell lymphoma after…
Far left ideology is to be afraid of open dialog
